Mithra Applies for Additional Estelle® Patent Based on Positive Hemostasis Data

  • Patent will strengthen and extend the existing Estelle® and E4 intellectual property estate
  • Positive hemostasis data differentiate Estelle® from commonly prescribed combined oral contraceptives

Liège, Belgium, 28 March 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has filed an additional patent application in Europe based on the data generated in the Estelle® hemostasis Phase II substudy. Estelle® is Mithra’s combined oral contraceptive (COC) candidate, composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP), and is currently being tested in two Phase III trials in Europe/Russia and in the US/Canada.